What the approval actually says
The FDA has approved Etcamah, camizestrant, as a daily pill for adults with oestrogen receptor-positive, HER2-negative advanced breast cancer, taken alongside a CDK4/6 inhibitor. It authorised the Guardant360 CDx blood test at the same time, to find the ESR1 change in fragments of tumour DNA floating in the bloodstream. Angelo de Claro, who directs the FDA's Oncology Center of Excellence, called it the first approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumour DNA before imaging shows the disease progressing.[1]
What the approval rests on is a length of time. In the trial, patients who switched to Etcamah went a median of 16 months before their cancer worsened, and those who stayed on their original hormone therapy went 9.2 months. That is time before growth, and the agency granted accelerated approval on it, the faster path for serious illness that turns on early signs of benefit. De Claro said in the same release that additional evidence is needed to confirm clinical benefit, and AstraZeneca must run more studies. Proof that patients live longer is not part of what was shown.[1]
The denominator
The FDA's own figures place the population. Fewer than 5 per cent of these patients have the ESR1 change when their cancer is first found to have spread. Nearly 40 per cent have it once the cancer starts growing again during estrogen-blocking therapy.[1]
So the change is largely something the treatment produces, and catching it early depends on drawing blood repeatedly while a patient is still doing well. A single test at diagnosis would miss most of it. That makes 16 months a figure for patients under regular monitoring inside a trial. An alternative reading is that the blood draws simply rode along with tumour scans that were happening anyway, in which case the added burden is small. How often blood was drawn is not part of what was reported, and how much of this benefit holds outside a trial hangs on it.[1]
The same question, a second time
The endpoint is doing the arguing again. In an earlier column on what recurrence-free survival sees and what it misses, the limit was how long patients had been followed. Here the limit is what was counted: 16 months against 9.2 months describes when the tumour grew, and the FDA has said plainly that additional evidence is needed to confirm clinical benefit.[1], [2]
The measurable form of the question sits in the confirmatory studies AstraZeneca has been told to run. If they keep the same population and the same comparator, the overall survival difference they report should come out smaller than the gap between 16 months and 9.2 months reported here, because moving a switch earlier buys time on the scan more readily than it buys years. That one number is what would turn an accelerated approval into a settled one, and it is the thing to read when it arrives.[1]